Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse

H E Gruber1, R K Rude

  • 1Department of Orthopaedic Surgery, Carolinas Medical Center, P.O. Box 32861, Charlotte, NC 28232, USA. hgruber@carolinas.org

Insights

Osteoprotegerin (OPG) treatment did not resolve hypercalcemia in magnesium-deficient mice. This suggests increased intestinal calcium absorption, not bone resorption, drives high calcium levels during Mg deficiency.

Area of Science:

  • Biochemistry
  • Physiology
  • Endocrinology

Background:

  • Dietary magnesium deficiency in mice causes hypercalcemia.
  • Osteoprotegerin (OPG) is known to inhibit osteoclastogenesis and bone resorption.

Purpose of the Study:

  • To investigate the role of osteoclastogenesis in hypercalcemia associated with magnesium deficiency.
  • To determine if OPG can correct hypercalcemia in magnesium-deficient mice.

Main Methods:

  • Mice were fed a magnesium-deficient diet or a control diet.
  • Mice received daily injections of OPG or vehicle for 12 days.
  • Serum calcium levels were measured.
  • Osteoclast morphology was examined using light and electron microscopy.

Main Results:

  • OPG treatment did not correct hypercalcemia in magnesium-deficient mice.
  • Serum calcium levels were elevated in both OPG-treated magnesium-deficient mice and OPG-treated control mice compared to vehicle-treated groups.
  • Ultrastructural examination revealed osteoclasts with reduced bone contact and absent ruffled borders in OPG-treated mice.

Conclusions:

  • Hypercalcemia in magnesium deficiency is not solely mediated by osteoclastic bone resorption.
  • Increased intestinal calcium absorption likely contributes to hypercalcemia during magnesium deficiency.
  • OPG's inhibition of osteoclast activity does not resolve hypercalcemia in this model.